Dabigatran etexilate

达比加群酯

Report date: 2026/05/26 20:00:28

Base Information

Drug NameDabigatran etexilate
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProthrombin inhibitors
TargetsProthrombin
Therapy Area/IndicationsVenous ThrombosisStrokeLiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesINTERNATIONAL BIO SERVICES CO LTDInstitute Of Liver And Biliary Sciences, India
Inactive CompaniesBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International GmbhBoehringer Ingelheim International Trading (Shanghai) Co Ltd
Active IndicationsVenous ThrombosisLiver Cirrhosis
Inactive IndicationsStroke

Other Information

ATC CodeB01AE07
Related LinksN/A